Slate Path Capital’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Slate Path Capital’s Portfolio KRSA Stock Details KRSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-51,126	Closed	-$927K	–	56
2024 Q3	$927K	Hold	51,126	–	–	0.01%	67
2024 Q2	$823K	Hold	51,126	–	–	0.02%	58
2024 Q1	$1.15M	Hold	51,126	–	–	0.02%	57
2023 Q4	$1.2M	Hold	51,126	–	–	0.03%	54
2023 Q3	$1.22M	Hold	51,126	–	–	0.03%	43
2023 Q2	$1.47M	Hold	51,126	–	–	0.05%	42
2023 Q1	$3.11M	Hold	51,126	–	–	0.15%	35
2022 Q4	$4.7M	Hold	51,126	–	–	0.25%	36
2022 Q3	$6.16M	Hold	51,126	–	–	0.4%	32
2022 Q2	$3.93M	Hold	51,126	–	–	0.25%	35
2022 Q1	$7.95M	Hold	51,126	–	–	0.41%	29
2021 Q4	$12.3M	Hold	51,126	–	–	0.65%	26
2021 Q3	$22M	Hold	51,126	–	–	1%	24
2021 Q2	$27.9M	Buy	51,126 +6,868	+16%	+$430K	1.56%	17
2021 Q1	$17.3M	Hold	44,258	–	–	1.12%	19
2020 Q4	$19M	Hold	44,258	–	–	1.03%	15
2020 Q3	$37.7M	Buy	44,258 +35,715	+418%	+$4.08M	2.14%	14
2020 Q2	$7.07M	Hold	8,543	–	–	0.42%	20
2020 Q1	$3.17M	Buy	+8,543	New	+$609K	0.24%	23
2019 Q4	–	Sell	-6,286	Closed	-$10.7M	–	28
2019 Q3	$10.7M	Buy	6,286 +1,186	+23%	+$256K	0.71%	15
2019 Q2	$8.18M	Buy	+5,100	New	+$1.44M	0.37%	19

Other funds holding KRSA

TCP

Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Slate Path Capital's KRSA Position: Q4 2024 in Review

Slate Path Capital sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q4 2024, closing a stake of 51,126 shares — an estimated $927K sold.

Slate Path Capital first reported a position in KRSA in Q2 2019 and held it in 21 quarters. The position peaked at $37.7M in Q3 2020. 18 funds tracked by Wall St. Rank hold KRSA as of Q4 2024.

Slate Path Capital reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Slate Path Capital sold 51,126 Korsana Biosciences, Inc. Common Stock shares in Q4 2024, an estimated $927K.
Slate Path Capital first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and held it in 21 quarters.
Slate Path Capital's Korsana Biosciences, Inc. Common Stock position peaked at $37.7M in Q3 2020.
18 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q4 2024.

Based on Slate Path Capital's 13F filing for Q4 2024, filed 14 Feb 2025.